Metastatic Urinary Bladder Carcinoma on Palliative Chemotherapy Showing Rapid Progression on Interim Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Bladder cancer (BC) is among the top ten most common cancer types globally. Muscle invasive BC has a high incidence of metastasis. Metastatic BC has a poor prognosis and limited treatment options. Here, we present a middle-aged man with oligometastatic BC, which was treated with palliative chemotherapy. He had significant clinical improvement. However, interim 18F-Fluorodeoxyglucose positron emission tomography/computed tomography demonstrates a rapid disease progression extensive metastasis.
References
1.
Giannatempo P, Alessi A, Miceli R, Raggi D, Fare E, Nicolai N
. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. Clin Genitourin Cancer. 2014; 12(6):433-9.
DOI: 10.1016/j.clgc.2014.03.007.
View
2.
Lu Y, Chen J, Liang J, Wang H, Lin C, Lin W
. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2011; 81(9):2411-6.
DOI: 10.1016/j.ejrad.2011.07.018.
View
3.
Alongi P, Caobelli F, Gentile R, Stefano A, Russo G, Albano D
. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2016; 44(2):224-233.
DOI: 10.1007/s00259-016-3500-8.
View
4.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F
. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108.
DOI: 10.1016/j.eururo.2016.06.010.
View
5.
Burger M, Catto J, Dalbagni G, Grossman H, Herr H, Karakiewicz P
. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2012; 63(2):234-41.
DOI: 10.1016/j.eururo.2012.07.033.
View